Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells 2,000 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) CEO Dipal Doshi sold 2,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $12.00, for a total value of $24,000.00. Following the completion of the transaction, the chief executive officer now directly owns 208,710 shares of the company’s stock, valued at approximately $2,504,520. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Dipal Doshi also recently made the following trade(s):

  • On Monday, June 27th, Dipal Doshi sold 4,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $48,000.00.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $12.80 on Friday. Entrada Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $36.85. The business has a 50-day moving average price of $9.70 and a 200 day moving average price of $9.28.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.69) earnings per share for the quarter.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently bought and sold shares of the company. New York State Common Retirement Fund purchased a new stake in Entrada Therapeutics during the 1st quarter worth approximately $46,000. Bank of New York Mellon Corp increased its stake in Entrada Therapeutics by 60.6% during the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock worth $206,000 after buying an additional 8,276 shares in the last quarter. Ghisallo Capital Management LLC purchased a new stake in Entrada Therapeutics during the 4th quarter worth approximately $257,000. Walleye Capital LLC purchased a new stake in Entrada Therapeutics during the 1st quarter worth approximately $419,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Entrada Therapeutics by 7.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,704 shares of the company’s stock worth $646,000 after buying an additional 4,685 shares in the last quarter. 86.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group cut their price target on Entrada Therapeutics from $22.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, May 24th.

About Entrada Therapeutics

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Featured Articles

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.